Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Srikanth Neelakantham"'
Autor:
Lu Gan, Kate Danis, Lloyd B. Klickstein, Jin Chen, Sachin Desai, Soniya Vaidya, Michael Badman, Bryan A. Laffitte, Srikanth Neelakantham, Jie Zhang
Publikováno v:
Clinical Pharmacology in Drug Development
Tropifexor (LJN452) is a potent, orally available, non–bile acid farnesoid X receptor agonist under clinical development for chronic liver diseases. Here, we present results from a first‐in‐human study of tropifexor following single‐ and mult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15da005aff7a9ae9eb30c35e52839cdb
https://doi.org/10.1002/cpdd.762
https://doi.org/10.1002/cpdd.762
Autor:
Eric Legangneux, Srikanth Neelakantham, Anne Gardin, Kasra Shakeri-Nejad, Cathy Gray, Swati Dumitras
Publikováno v:
Clinical Therapeutics. 42:175-195
Purpose The goal of this study was to assess the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of intravenous (IV) siponimod in healthy subjects. Methods This randomized, open-label study was conducted in 2 parts. In Part 1, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3787115e5c441ee610b2dc0dc64a039
https://doi.org/10.1016/j.clinthera.2019.11.014
https://doi.org/10.1016/j.clinthera.2019.11.014
Autor:
Anne Gardin, Swati Dumitras, Srikanth Neelakantham, Felix Huth, Andrea Feller, Kasra Shakeri-Nejad
Publikováno v:
European Journal of Clinical Pharmacology. 75:1565-1574
To evaluate the PK and safety of siponimod, a substrate of CYP2C9/3A4, in the presence or absence of a CYP3A4 inhibitor, itraconazole. This was an open-label study in healthy subjects (aged 18–50 years; genotype: CYP2C9 *1*2 [cohort 1; n = 17] or *
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11214a189361ffc50b5764ae3d7ce871
https://doi.org/10.1007/s00228-019-02729-7
https://doi.org/10.1007/s00228-019-02729-7
Publikováno v:
Psychopharmacology
Abuse and misuse of prescription drugs remains an ongoing concern in the USA and worldwide; thus, all centrally active new drugs must be assessed for abuse and dependence potential. Sphingosine-1-phosphate (S1P) receptor modulators are used primarily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e945f3f02b07f0b77af8d91b7fb0f37a
https://pubmed.ncbi.nlm.nih.gov/34773483
https://pubmed.ncbi.nlm.nih.gov/34773483
Autor:
Anne Gardin, Felix Huth, Antonia M Davidson, Eric Legangneux, Kasra Shakeri-Nejad, Cathy Gray, Swati Dumitras, Srikanth Neelakantham
Publikováno v:
European Journal of Clinical Pharmacology. 74:1593-1604
To assess the potential pharmacokinetic (PK) interactions between siponimod and rifampin, a strong CYP3A4/moderate CYP2C9 inducer, in healthy subjects. This was a confirmatory, open-label, multiple-dose two-period study in healthy subjects (aged 18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc0b6929bedb3f3a49b7da486da9afd4
https://doi.org/10.1007/s00228-018-2533-2
https://doi.org/10.1007/s00228-018-2533-2
Autor:
Srikanth Neelakantham, Ronenn Roubenoff, Tania Garito, Daniel Rooks, Linda Morrow, Charles D. Meyers, Olivier Petricoul, Lee Anne Filosa, Katherine Gomez, Marcus Hompesch, Marjorie Zakaria, Monte S. Buchsbaum, Therese Swan, Didier Laurent
Publikováno v:
Diabetes, Obesity and Metabolism. 20:94-102
Background Skeletal muscle is a key mediator of insulin resistance. Bimagrumab, an antibody against activin receptor type II (ActRII), prevents binding of negative muscle regulators, like myostatin, and increases lean mass and decreases fat mass in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c77d2496f8c9f387521d5a9d92801b3
https://doi.org/10.1111/dom.13042
https://doi.org/10.1111/dom.13042
Autor:
Srikanth Neelakantham, Xuemei Tan, Kasra Shakeri-Nejad, Angela Dodman, Eric Legangneux, Sampath Kalluri, Anne Gardin
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 55:54-65
To investigate the pharmacokinetics (PK), safety, and tolerability of siponimod and selected inactive metabolites (M3 and M5) in subjects with varying degrees of renal impairment (RI) compared to demographically matched healthy subjects (HS).The stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ba731c3932be5dbf933e186c2ed2ed2
https://doi.org/10.5414/cp202608
https://doi.org/10.5414/cp202608
Autor:
Srikanth Neelakantham, Tapan K. Majumdar, Aishwarya Movva, Atish Salunke, Charles D. Meyers, Kenneth Kulmatycki, Anne Crissey, Jin Chen, Adele Noe
Publikováno v:
Clinical Pharmacology in Drug Development. 5:450-459
Pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, has been studied in familial chylomicronemia syndrome. To evaluate the effects of supratherapeutic concentrations of pradigastat on the QTc interval, 2 studies were conducted. The first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0cbbad0fd4abf66631d02bf64754252
https://doi.org/10.1002/cpdd.278
https://doi.org/10.1002/cpdd.278
Autor:
David Andrew Sandham, Michael Larbig, Wande Osuntokun, Srikanth Neelakantham, Gerald Dubois, Walid Elbast, Lien Gheyle, Eva Vets, Paul Goldsmith, Markus Weiss, Veit J. Erpenbeck
Publikováno v:
Clinical Pharmacology in Drug Development
We evaluated the pharmacokinetics (PK), safety, and tolerability of a novel oral CRTh2 antagonist, fevipiprant (QAW039), in healthy subjects. Peak concentrations of fevipiprant in plasma were observed 1‒3 hours postdosing. Concentrations declined i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d96f10e3d4a588216c2f462094bb3571
https://doi.org/10.1002/cpdd.244
https://doi.org/10.1002/cpdd.244
Autor:
Thomas Langenickel, Sam Rebello, Iris Rajman, Marion Dahlke, Lu Gan, Wei Zhou, Xuemin Jiang, Srikanth Neelakantham, Mizuki Akahori, Gangadhar Sunkara, Christine Reynolds, Anisha E. Mendonza, Joanne Nguyen, Parasar Pal, Therese Swan
Publikováno v:
Clinical Pharmacology in Drug Development. 5:27-39
LCZ696 is a novel angiotensin receptor neprilysin inhibitor in development for the treatment of cardiovascular diseases. Here, we assessed the potential for pharmacokinetic drug-drug interaction of LCZ696 (400 mg, single dose or once daily [q.d.]) wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::921b23506211a94c645d00f7ec8c61ef
https://doi.org/10.1002/cpdd.181
https://doi.org/10.1002/cpdd.181